ORIGINAL ARTICLE
Role of mast cells in the pathogenesis of liver fibrosis in nonalcoholic fatty liver disease
1
Department of Histology and Embryology, Interfaculty Chair of Anatomy and Histology, Medical University of Lodz, Lodz, Poland
2
Information Technology Institute, Technical University of Lodz, Lodz, Poland
3
Department of General and Transplant Surgery, Norbert Barlicki Memorial Teaching Hospital No. 1, Medical
University of Lodz, Lodz, Poland
Submission date: 2019-04-16
Final revision date: 2019-08-01
Acceptance date: 2019-08-07
Publication date: 2020-05-20
Pol J Pathol 2020;71(1):38-45
KEYWORDS
TOPICS
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD), a very common comorbidity of obesity, may progress from simple steatosis to nonalcoholic steatohepatitis and liver cirrhosis. The aim of this study was to determine whether mast cells (MCs) participate in the pathogenesis of liver fibrosis in patients with NAFLD.
Liver specimens collected either from obese subjects or the control group were prepared for histological examination. The patients were divided into groups depending on inflammation and fibrosis grade, and the mean total number of mast cells/mm2 and those located only in portal areas/ fibrous septa or within lobules were calculated for each grade. Mast cells were detected by pina-cyanol erythrosinate staining.
There was a strong positive correlation between the number of mast cells, especially those located within portal areas and fibrous septa, and the liver fibrosis grade (r = 0.736, p < 0.0001). No similar dependency between the number of mastocytes within lobules and liver fibrosis grade was identified.
The results from this study suggest the involvement of mast cells from portal areas and fibrous septa in the pathogenesis of liver fibrosis in patients with NAFLD.
Liver specimens collected either from obese subjects or the control group were prepared for histological examination. The patients were divided into groups depending on inflammation and fibrosis grade, and the mean total number of mast cells/mm2 and those located only in portal areas/ fibrous septa or within lobules were calculated for each grade. Mast cells were detected by pina-cyanol erythrosinate staining.
There was a strong positive correlation between the number of mast cells, especially those located within portal areas and fibrous septa, and the liver fibrosis grade (r = 0.736, p < 0.0001). No similar dependency between the number of mastocytes within lobules and liver fibrosis grade was identified.
The results from this study suggest the involvement of mast cells from portal areas and fibrous septa in the pathogenesis of liver fibrosis in patients with NAFLD.
REFERENCES (55)
1.
Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
2.
Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
3.
Wells RG, Kruglov E, Dranoff JA. Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Lett 2004; 559: 107-110.
4.
Kisseleva T, Uchinami H, Feirt N, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006; 45: 429-438.
6.
Desai HG. Cryptogenic cirrhosis: a vanishing entity. J Assoc Physicians India 2009; 57: 251-255.
7.
Wynn TA. Cellular and molecular mechanizms of fibrosis, J Pathol 2008; 214: 199-210.
8.
Schuppan D. Structure of extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 1990; 10: 1-10.
9.
Reeves HL, Friedman SL. Activation of hepatic stellate cells: a key issue in liver fibrosis. Front Biosci 2002; 7: 808-826.
10.
Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest 2004; 84: 153-159.
11.
Forbes SJ, Russo FP, Rey V, et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004; 126: 955-963.
12.
Gressner AM, Weiskirchen R, Breitkopf K, et al. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: 793-807.
14.
Sawicki W, Malejczyk J. Tkanka ³¹czna w³aœciwa. In: Histologia. Sawicki W (ed.). 6th ed. Wydawnictwo Lekarskie PZWL, Warszawa 2012; 147-173.
15.
Kumar D, Pandya SK, Varshney S, et al. Temporal immunometabolic profiling of adipose tissue in HFD-induced obesity: manifestations of mast cells in fibrosis and senescence. Int J Obes (Lond) 2019; 43: 1281-1294.
16.
Lin KQ, Zhu LB, Zhang XM, et al. Role of mast cells in estrogen-mediated experimental endometriosis in rats. Zhejiang Da Xue Xue Bao Yi Xue Ban 2015; 44: 269-277.
17.
Zhu TH, Ding SJ, Li TT, et al. Estrogen is an important mediator of mast cell activation in ovarian endometriomas. Reproduction 2018; 155: 73-83.
18.
Hirai S, Ohyane C, Kim YI, et al. Involvement of mast cells in adipose tissue fibrosis. Am J Physiol Endocrinol Metab 2014; 306: 247-255.
19.
Kazama I, Baba A, Endo Y, et al. Mast cell involvement in the progression of peritoneal fibrosis in rats with chronic renal failure. Nephrology (Carlton) 2015; 20: 609-616.
20.
Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 2013; 71: 549-574.
21.
El-Mohandes EM, Moustafa AM, Khalaf HA, et al. The role of mast cells and macrophages in amiodarone induced pulmonary fibrosis and the possible attenuating role of atorvastatin. Biotech Histochem 2017; 92: 467-480.
22.
Armbrust A, Batusic D, Ringe B, et al. Mast cells distribution in human liver disease and experimental rat liver fibrosis. Indications for mast cell participation in development of liver fibrosis. J Hepatol 1997; 26: 1042-1054.
23.
Farreil DJ, Hines JE, Walls AF, et al. Intrahepatic mast cells in chronic liver diseases. Hepatology 1995; 22: 1175-1181.
24.
Akiyoshi H, Terada T: Mast cell, myofibroblast and nerve terminal complexes in carbon tertrachloride-induced cirrhotic rat livers. J Hepatol 1998; 29: 112-119.
25.
Yamashiro M, Kouda W, Kono N, et al. Distribution of intrahepatic mast cells in various hepatobiliary disorder. An immunohistochemical study. Virchows Arch 1998; 433: 471-479.
26.
Sugihara A, Tsujimura T, Fujita Y, et al. Evaluation of role of mast cells in the development of liver fibrosis using mast cell-deficient rats and mice. J Hepatol 1999; 30: 859-867.
27.
Bensley SH. Pinacyanol erythrosinate as a stain for mast cells. Stain Technol 1952; 27: 269-273.
28.
Brunt EM, Kleiner DE, Wilson LA, et al. NASH Clinical Research Network: Portal Chronic Inflammation in Nonalcoholic Fatty Liver Disease (NAFLD): A Histologic Marker of Advanced NAFLD – Clinicopathologic Correlations from the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology 2009; 49: 809-820.
29.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
30.
Basaranoglu M, Kayacetin S, Yilmaz N, et al. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 2223-2226.
31.
Chavez-Tapia NN, Uribe M, Ponciano-Rodriguez G, et al. New insights into the pathophysiology of nonalcoholic fatty liver disease. Ann Hepatol 2009; 8: Suppl 1: 9-17.
32.
Stoyanova II. Relevance of Mast cells and hepatic lobule innervation to liver injury. Rom J Gastroenterol 2004; 13: 203-209.
33.
Liaskou E, Wilson DV, Oo YH. Innate Immune Cells in Liver Inflammation. Mediators Inflamm 2012; 2012: 949157.
34.
Gruber BL, Kew RR, Jelaska A, et al. Human Mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblasts chemotaxis. J immunol 1997; 158: 2310-2317.
35.
Ruoss SJ, Hartmann T, Caughey GH. Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest 1991; 88: 493-499.
36.
Hügle T. Beyond allergy: the role of mast cells in fibrosis. Swiss Med Wkly 2014; 144: w13999.
38.
Valfrè BL, Novo E, Cannito S, et al. Angiogenesis and liver fibrogenesis. Histol Histopathol 2009; 24: 1323-1341.
39.
Groneberg DA, Bester C, Grützkau A, et al. Mast cells and vasculature in atopic dermatitis – potential stimulus of neoangiogenesis. Allergy 2005; 60: 90-97.
40.
Puxeddu I, Ribatti D, Crivellato E, et al. Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol 2005; 116: 531-536.
41.
Crivellato E, Nico B, Ribatti D. Mast cell contribution to tumor angiogenesis: a clinical approach. Eur Cytokine Netw 2009; 20: 197-206.
42.
Qu Z, Liebler JM, Powers MR, et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol 1995; 147: 564-573.
43.
Sörbo J, Jakobson A, Norrby K. Mast cell histamine is angiogenic through receptors for histamine 1 and histamine 2. Int J Exp Pathol 1994; 75: 43-50.
44.
Ribatti D, Roncali L, Nico B, et al. Effects of exogenous heparin on the vasculogenesis of the chorioallantoic membrane. Acta Anat (Basel) 1987; 130: 257-263.
45.
Kanbe N, Tanaka A, Kanbe M, et al. Human mast cells produce matrix metalloproteinase 9. Eur J Immunol 1999; 29: 2645-2649.
46.
Fernández M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620.
47.
Amarapurkar AD, Amarapurkar DN, Vibhav S, et al. Angiogenesis in chronic liver disease. Ann Hepatol 2007; 6: 170-173.
48.
Ciupiñska-Kajor M, Hartleb M, Kajor M, et al. Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. Hepatol Int 2013; 7: 233-240.
49.
Schluger LK, Sheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971-976.
50.
Bonnard P, Lescure FX, Amiel C, et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat 2007; 14: 806-811.
51.
Charlton M, Krishnan A, Viker K, et al. Fast food diet Mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011; 301: 825-834.
52.
Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004; 39: 1631-1638.
53.
Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014; 20: 2515-2532.
54.
Colombat M, Charlotte F, Ratziu V, et al. Portal lymphcytic infiltrate in alcoholic liver disease. Hum Pathol 2002; 33: 1170-1174.
55.
Liew PL, Lee WJ, Lee YC, et al. Hepatic histopathology of morbid obesity: concurence of Rother forms of chronic liver disease. Obes Surg 2006; 16: 1584-1593.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
